#ADTX hashtag - Bluesky

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026 Aditxt, Inc., a social innovation platform accelerating promising health innovations, announced today that it will effect a 1- for-8 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on March 9, 2026, the Company’ s common stock will trade on a post-split basis under the same symbol ADTX.

3 weeks ago

#ADTX Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026

www.stocktitan.net/news/ADTX/aditxt-inc-nas...

0 0 0 0

Stock Master

@stockmaster70.bsky.social

4 months ago

📢 Stocks Trending NOW: #MU #GME #CME #NBIS #ADTX #AA #CRWV #BEAT #ORCL #BMNR

0 0 0 0

4 months ago

Breaking News: ( NASDAQ: #ADTX ) InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Outlines bitXbio Strategy and Proposes Corporate Name Change

0 0 0 0

Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta’s Planned IPO, And Evofem’s Plan to Regain a National Listing Aditxt (NASDAQ: ADTX) filed a preliminary proxy seeking shareholder approval for an employee stock purchase plan and a non-binding advisory vote to change its name to bitXbio as part of a strategic shift to a platform combining public markets, blockchain/Web3 and life sciences.ThebitXbio strategy describes a planned Digital Asset Treasury (DAT) with a crypto reserve, a native utility token, and tokenized venture representations, but Aditxt currently holds no digital assets. The company highlighted Pearsanta’s planned IPO in 2026 (subject to market conditions) and disclosed holdings in Evofem: Series F-1 preferred stated value $26,280,000 and convertible notes $3,730,769.

4 months ago

#ADTX Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta’s Planned IPO, And Evofem’s Plan to Regain a National Listing

www.stocktitan.net/news/ADTX/aditxt-provide...

0 0 0 0

4 months ago

News; ( NASDAQ: #ADTX ) ADTX - Historical Earnings Price Analysis

0 0 0 0

4 months ago

News; ( NASDAQ: #ADTX ) ADTX - Historical Price Movements Surrounding Earnings

0 0 0 0

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025 Aditxt, Inc., a social innovation platform accelerating promising health innovations, announced today that it will effect a 1- for-113 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on November 3, 2025, the Company’ s common stock will trade on a post-split basis under the same symbol ADTX.

5 months ago

#ADTX Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025

www.stocktitan.net/news/ADTX/aditxt-inc-nas...

0 0 0 0

Evofem Announces Voting Results from Special Meeting of Stockholders Evofem Biosciences (OTCID: EVFM) announced on October 20, 2025 that its stockholders did not approve the Amended and Restated Merger Agreement with Aditxt (NASDAQ: ADTX), and Evofem has exercised its rights to terminate the Merger Agreement.The company said it will pivot to regain a national listing for its stock and secure growth capital to catalyze net sales while targeting sustainable positive EBITDA in 2027. Evofem noted a continuing collaboration with Aditxt to commercialize Mitomic diagnostic tests under their September 2024 agreement.Evofem commercializes two FDA-approved sexual health products, PHEXXI vaginal gel and SOLOSEC oral granules, and reported 2024 was its fourth consecutive year of net sales growth.

5 months ago

#EVFM #ADTX Evofem Announces Voting Results from Special Meeting of Stockholders

www.stocktitan.net/news/EVFM/evofem-announc...

0 0 0 0

Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms Evofem Biosciences (OTCID: EVFM) reported significant success from its August 2025 "Say Vagina" campaign, designed to normalize clinical anatomical language. The campaign generated over 2.5 million views across social media platforms and drove a 130% increase in traffic to PHEXXI.com, the company's hormone-free contraceptive product website.Key achievements include PHEXXI becoming the #1 most followed contraceptive brand among healthcare providers, and CEO Saundra Pelletier's Instagram reach growing by 400%. The company plans to launch SayVaginaStore.com in September, with all proceeds from campaign merchandise being donated to selected sexual and reproductive health charities.

6 months ago

#EVFM #ADTX Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms

www.stocktitan.net/news/EVFM/evofem-s-say-v...

0 0 0 0

Majority Support Secured: Evofem-Aditxt Women's Health Merger Heads to Critical September Vote Women's health company Evofem has secured 53.71% voting power support for merger with Aditxt, including Series E-1 and G-1 holders. Special stockholder meeting scheduled for September 26.

6 months ago

#EVFM #ADTX Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting

www.stocktitan.net/news/EVFM/evofem-anticip...

0 0 0 0

FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis Evofem Biosciences (OTCID: EVFM) announced that a new U.S. patent for SOLOSEC®, their single-dose oral treatment for bacterial vaginosis and trichomoniasis, has been listed in the FDA Orange Book. The newly listed patent (No. 12,280,037) covers the method, pharmaceutical composition, and use in treating trichomoniasis, extending market exclusivity until December 2041.SOLOSEC is notable as the first and only FDA-approved single-dose oral treatment for both bacterial vaginosis and trichomoniasis. The company is currently conducting a Phase 4 clinical trial comparing SOLOSEC's effectiveness and cost-effectiveness against metronidazole in treating T. vaginalis infections, which affect an estimated 6.9 million new cases annually in the U.S.

7 months ago

#EVFM #ADTX FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

www.stocktitan.net/news/EVFM/fda-orange-boo...

0 0 0 0

Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update Evofem Biosciences (OTCID: EVFM) reported improved financial results for Q2 2025, with net sales increasing 16% to $4.8 million compared to $4.2 million in Q2 2024. The company reduced its loss from operations to $1.3 million from $1.4 million year-over-year.Key developments include advancing strategies to reduce manufacturing costs by 50% for PHEXXI and SOLOSEC, expanding into UAE markets, and progress in clinical trials. The company is proceeding with plans to become a wholly-owned subsidiary of Aditxt, having raised $2.4 million through senior subordinated notes and warrants in Q2 2025.The company reported a net loss of $(0.02) per share compared to a net income of $0.02 per share in Q2 2024, with cash and equivalents of $0.7 million as of June 30, 2025.

7 months ago

#EVFM #ADTX Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

www.stocktitan.net/news/EVFM/evofem-reports...

0 0 0 0

Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy Evofem Biosciences (NASDAQ:EVFM) has achieved significant social media success with its non-hormonal birth control brand PHEXXI through a viral TikTok campaign focused on microfeminism. The campaign, which generated over 10 million views and 24,000+ comments, sparked widespread media coverage from major outlets including BuzzFeed, MSN, and Scary Mommy.The campaign's success aligns with PHEXXI's brand positioning as a hormone-free birth control option that emphasizes women's choice and autonomy. CEO Saundra Pelletier highlighted the brand's commitment to challenging norms in women's health, with plans for continued bold marketing initiatives in August.

8 months ago

#EVFM #ADTX Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy

www.stocktitan.net/news/EVFM/phexxi-a-non-h...

0 0 0 0

Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization Aditxt (Nasdaq: ADTX) has unveiled its bitXbio™ Plan, a novel Bitcoin-backed treasury strategy combined with an equity line facility to support biotech commercialization. The company plans to establish a Bitcoin reserve and utilize its $125 million equity line facility, with current authorization to sell up to 50 million shares of common stock.The initiative aims to strengthen Aditxt's balance sheet and align its market value with upcoming commercialization activities. A key milestone in the strategy is the planned IPO of Pearsanta in 2026. The company operates two main programs focused on autoimmunity and early disease/cancer detection, pursuing growth through acquiring, building, and capitalizing high-growth ventures in health and biotechnology.

8 months ago

#ADTX Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization

www.stocktitan.net/news/ADTX/aditxt-unveils...

0 0 0 0

Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting Evofem Biosciences (OTCPK: EVFM) presented promising study results for SOLOSEC (secnidazole) in treating recurrent bacterial vaginosis (BV) at the 2025 ACOG Annual Meeting. The clinical study of 24 women showed that once-weekly dosing of SOLOSEC 2g oral granules demonstrated efficacy comparable or potentially superior to current CDC-recommended suppressive treatments. BV affects approximately 21 million U.S. women, with up to 50% experiencing recurrence within six months of treatment. The BV treatment market is projected to reach $1.0 billion in the U.S. by 2033. While SOLOSEC is currently approved for BV treatment in women aged 12 and older, its use in recurrent BV remains investigational. The simplified once-weekly oral dosing regimen could potentially improve treatment adherence compared to more complex existing protocols.

9 months ago

#EVFM #ADTX Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting

www.stocktitan.net/news/EVFM/notable-data-o...

0 0 0 0

Saundra Pelletier, Evofem Biosciences’ CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6 Aditxt (NASDAQ: ADTX) announced its upcoming Weekly Update event on June 6, 2025, featuring CEO Amro Albanna and three prominent healthcare leaders. The virtual event will include Dr. Friedrich Kapp, co-CEO of Adimune, discussing ADI-100, an antigen-specific gene therapy for autoimmune diseases; Chris Mitton, president of Pearsanta, presenting on Mitomic diagnostic tests for endometriosis and prostate cancer; and Saundra Pelletier, CEO of Evofem Biosciences, sharing insights on women's health. The event will take place at 11:30 a.m. ET via Zoom, highlighting developments in immune therapy, disease detection, and women's healthcare innovations.

9 months ago

#ADTX Saundra Pelletier, Evofem Biosciences’ CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

www.stocktitan.net/news/ADTX/saundra-pellet...

0 0 0 0

Aditxt Scraps $16M Appili Therapeutics Merger: Strategic Shift Saves Millions in Deal Costs Latest strategic pivot eliminates $16M in obligations as biotech firm exits Appili arrangement. Get insights on what this means for Aditxt's future direction.

10 months ago

#ADTX Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

www.stocktitan.net/news/ADTX/aditxt-announc...

0 0 0 0

Game-Changing Blood Test Could Slash 7-Year Endometriosis Diagnosis Delays Revolutionary blood-based diagnostic aims to transform endometriosis detection, potentially helping millions of women avoid invasive procedures. Full study details inside.

11 months ago

#ADTX Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

www.stocktitan.net/news/ADTX/aditxt-subsidi...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

11 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with declining money flow, Tue Apr 15th - #NFBK #MRBK #MQ #FIP #DXLG #CLRB #BCTX #ADTX #SD #OIS #NVRO #GTN #ACR - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

11 months ago

JUST IN: ( NASDAQ: #ADTX ) InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Advances Autoimmune Therapy Following Positive Mayo Clinic Study on ADI-100

0 0 0 0

Aditxt Secures Nasdaq Future: Key Corporate Updates Coming Today Aditxt meets Nasdaq listing requirements and schedules crucial investor update covering strategic transactions and subsidiary operations. Full analysis inside.

11 months ago

#ADTX Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

www.stocktitan.net/news/ADTX/aditxt-weekly-...

0 0 0 0

$117M Federal Funding Applications: Aditxt and Appili CEOs to Unveil Major Biodefense Strategy Learn how Aditxt's $117M funding applications and enhanced biodefense program terms could accelerate growth. Track record: $33.2M in government awards. Full analysis inside.

11 months ago

#ADTX Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

www.stocktitan.net/news/ADTX/appili-preside...

0 0 0 0

Game-Changing Cancer Detection: Aditxt's New DNA Platform Could Transform Early Diagnosis Groundbreaking adductomics platform enables early DNA mutation detection for cancer prevention. Learn how this acquisition transforms Aditxt's diagnostic capabilities.

1 year ago

#ADTX Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

www.stocktitan.net/news/ADTX/upcoming-aditx...

0 0 0 0

1 year ago

Just In: ( NASDAQ: #ADTX ) InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Acquires Patents for DNA Damage Detection in Cancer Prevention

0 0 0 0